CMES4 Updates in Familial Hypercholesterolemia: The Future of Cholesterol Management

Program: CMES Ancillary Events
Clinical Session
Saturday, April 2, 2016: 5:45 AM-8:00 AM
Pacific Ballroom (The Renaissance)
Supported by an educational grant from Amgen, Inc.

Registration is required for this session:

Learning Objectives:

Upon completing this activity, learners will be better able to:

  • Summarize the genetic underpinnings of familial hypercholesterolemia and impact on cardiovascular outcomes
  • Evaluate strategies to optimize commonly used lipid-lowering therapies in patients with familial hypercholesterolemia
  • Describe the mechanism of action and most current information of the safety and efficacy of newer therapies to treat familial hypercholesterolemia (i.e., lomitapide, mipomersen, PCSK9 inhibitors)
  • Assess the value of newer therapies to treat patients with familial hypercholesterolemia and apply treatment
6:00 AM

Anne Carol Goldberg, MD, Endocrinology, Metabolism and Lipid Research, Washington University in St. Louis, Saint Louis, MO
Disclosure Not Provided: ACG
6:05 AM

Ira Jay Goldberg, MD, Medicine, New York University, New York, NY
Disclosures:
IJG: Ad Hoc Consultant, Amgen, Ad Hoc Consultant, Sanofi, Investigator, Jansen Pharmaceuticals, Investigator, Ionis, Ad Hoc Consultant, Boeringer I.
6:30 AM

Robert Harold Eckel, MD, Anchutz Medical Campus, Aurora, CO
Disclosures:
RHE: Consultant, Sanofi, Consultant, Sanofi.
6:55 AM

P. Barton Duell, MD, Knight Cardiovascular Institute, Oregon Health and Science University, Portland, OR
Disclosures:
PBD: Investigator, Amgen, Consultant, Kaneka, Research Funding, Retrophin, Investigator, Regeneron, Investigator, Ionis/ISIS, Speaker, Sanofi, Consultant, Genzyme Corporation, Investigator, Genzyme Corporation, Consultant, Lilly USA, LLC.
7:25 AM

Anne Carol Goldberg, MD, Endocrinology, Metabolism and Lipid Research, Washington University in St. Louis, Saint Louis, MO
Disclosure Not Provided: ACG
See more of: CMES Ancillary Events